The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.
Hakan Mellstedt
Employment or Leadership Position - Kancera AB
Consultant or Advisory Role - Kancera AB
Stock Ownership - Kancera AB
Honoraria - Kancera AB
Salam Khan
No relevant relationships to disclose
Jan Vågberg
Employment or Leadership Position - Kancera AB
Other Remuneration - Kancera AB
Styrbjörn Byström
Employment or Leadership Position - Kancera AB
Johan Schultz
Employment or Leadership Position - Kancera AB
Mohammad Hojat Farsangi
Stock Ownership - Kancera AB (I)
Ladan Mansouri
No relevant relationships to disclose
Amir Hossein Danesh Manesh
Stock Ownership - Kancera AB
Anders Österborg
Consultant or Advisory Role - Kancera AB
Stock Ownership - Kancera AB
Ali Moshfegh
No relevant relationships to disclose